Transgenic mice replicating hepatitis B virus but lacking expression of the major HBsAg

Leonie Halverscheid1, Nina K Mannes, Robert Weth

  • 1Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.

Journal of Medical Virology
|February 26, 2008
PubMed

Insights

New Hepatitis B Virus (HBV) transgenic mice lack small envelope protein (HBsAg) expression. These mice are valuable for studying HBV assembly, immune responses, and developing new antiviral vaccines.

Area of Science:

  • Virology
  • Immunology
  • Hepatology

Background:

  • Hepatitis B Virus (HBV) infection is a major global health concern.
  • The small envelope protein (HBsAg) plays a critical role in HBV assembly and pathogenesis.
  • Understanding HBsAg's function is crucial for developing effective antiviral strategies and vaccines.

Purpose of the Study:

  • To generate and characterize HBV transgenic mice lacking HBsAg expression.
  • To investigate the role of HBsAg in viral replication, assembly, and pathogenesis.
  • To establish a novel animal model for HBV research.

Main Methods:

  • Generation of transgenic mice using a terminally redundant viral DNA construct (HBV 1.4).
  • Analysis of viral mRNA expression in various organs.
  • Detection of viral particles and proteins in sera and liver tissue.
  • Histopathological examination of liver for signs of inflammation.

Main Results:

  • Transgenic mice successfully replicated the HBV genome but lacked HBsAg expression.
  • Viral mRNA was detected in liver and kidneys.
  • No infectious progeny, viral particles, or HBsAg were found in sera.
  • Hepatocytes showed expression of non-secreted LHBs and MHBs proteins without endoplasmic reticulum accumulation or necroinflammatory hepatitis.

Conclusions:

  • The generated HBV transgenic mice lacking HBsAg are a viable model for studying HBV immunopathogenesis.
  • This model is suitable for investigating the role of HBsAg in viral assembly and antiviral immune responses.
  • These mice offer a promising platform for the development of novel antiviral vaccines against HBV.